Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 6/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.34 |
| ▸ | FDPS | P14324 | 7/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24540959 | 0.91 | DNM1 (0.54) | DNM1TSHRALDH1A1THRBGGPS1 | |
| SCHEMBL24919594 | 0.86 | DNM1 (0.48) | DNM1TSHRALDH1A1THRBGGPS1 | |
| SCHEMBL23902941 | 0.86 | DNM1 (0.48) | DNM1TSHRALDH1A1LMNA | |
| SCHEMBL23902959 | 0.86 | DNM1 (0.46) | DNM1TSHRALDH1A1LMNA | |
| SCHEMBL22017088 | 0.84 | GGPS1 (0.42) | DNM1TSHRTHRBGGPS1FDPS | |
| SCHEMBL20589570 | 0.83 | TSHR (0.53) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL8685403 | 0.83 | TSHR (0.53) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL8687541 | 0.83 | TSHR (0.53) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL8684875 | 0.83 | TSHR (0.53) | TSHRTHRBGGPS1FDPS | |
| SCHEMBL8685221 | 0.83 | TSHR (0.53) | TSHRTHRBGGPS1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10479793-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479793-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | TYK2, IL2, JAK3 | DNM1 2714/4885TSHR 1170/4885ALDH1A1 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.